WorldCat Identities

Tornesello, Marialina

Overview
Works: 6 works in 6 publications in 1 language and 11 library holdings
Roles: Contributor
Publication Timeline
.
Most widely held works by Marialina Tornesello
A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice by Maria Tagliamonte( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma by Valeria De Giorgi( )

1 edition published in 2009 in English and held by 2 WorldCat member libraries worldwide

Role of TP53 polymorphisms in sub-Saharan mucosal cancers by Franco M Buonaguro( )

1 edition published in 2010 in English and held by 2 WorldCat member libraries worldwide

HPV monitoring in kidney transplanted patients by Franco M Buonaguro( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders by Luigi Buonaguro( )

1 edition published in 2010 in English and held by 2 WorldCat member libraries worldwide

P-G5 Differential immune response to HCV peptides as cancer-progression biomarkers of HCV-infections( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : HCV infections are the main cause of chronic liver disease and in part of lymphoproliferative disorders. Most HCV infections (>90%) determine chronic hepatitis, 30% of which progress to liver cirrhosis and 3% annually to Hepatocellular Carcinoma (HCC). The progression rate is mainly articulated in low (>40 years) and high (<10 years) speed progressors, with the latter being associated to male gender, <40 years of age, >150mL daily alcohol consumption. Current progression markers are mainly based on biochemical evaluation of liver damage (elevation of alanine and aspartate transaminases) and inflammation (elevation of alpha-fetoprotein). Such markers are not specific and elevated also for other infections (ie, HBV and HCMV) or metabolic disorders (ie, steatosis). Specific HCV-related markers would be relevant to identify HCV co-factors and to select high priority people for direct anti-viral treatment. To identify HCC progression markers, samples from HCV+ patients at different infection stage have been analyzed on the HCV-peptide platform newly developed by JPT Peptide Technologies GmbH (Germany). It covers the complete HCV-protein arrays with >3000 overlapping 15-amino-acid-long peptides from all structural and non structural HCV proteins. The currently available data (from 7 HCV+ asymptomatic, 5 HCV+ with cryoglobulinemia, 9 HCV cirrhosis/HCC and 5 HCV− patients) demonstrates that in asymptomatic patients the level of anti-HCV is in general very low (including anti-capsid/core proteins), while high levels of immunoresponse anti-non-structural proteins is present in patients with liver cancer. Confirmation of such data would support the anti-non structural response as biomarker of cancer progression in HCV+ patients
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.96 (from 0.88 for P-G5 Diffe ... to 0.97 for A novel mu ...)

WorldCat IdentitiesRelated Identities
Languages